International Patent: DOUBLE-STRANDED SIRNA ANALOG FOR INHIBITING ACVR2A EXPRESSION AND USE THEREOF

GENEVA, Oct. 9 -- SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. filed a patent application (CN2026/088005) for “DOUBLE-STRANDED SIRNA ANALOG FOR INHIBITING ACVR2A EXPRESSION AND USE THEREOF”. With publication no. WO/2026/208945, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C12N 15/113

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....